Trusted Resource for Clinical Trials, Protocols & Progress
Submitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) is the culmination of years of drug development, involving preclinical, clinical, and manufacturing data. To avoid delays, Refuse-to-File (RTF) letters, or regulatory setbacks, it is essential to prepare a comprehensive submission package that meets FDA’s structural, technical, and content requirements.
Click to read the full article.
Global pharmaceutical development hinges on understanding the regulatory frameworks of major markets—most notably, the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). While both agencies aim to ensure the safety, efficacy, and quality of medicinal products, the pathways to approval under each system differ significantly in structure, submission strategy, timelines, and post-approval obligations.
Click to read the full article.
A Biologics License Application (BLA) is the critical regulatory submission that allows a sponsor to market a biologic product in the United States. Unlike NDAs (New Drug Applications), which cover chemically synthesized drugs, BLAs cover complex biologics such as monoclonal antibodies, vaccines, gene therapies, blood products, and recombinant proteins.
Click to read the full article.
A Marketing Authorization Application (MAA) is the regulatory gateway for obtaining approval to market a medicinal product in the European Union (EU) and European Economic Area (EEA). Overseen by the European Medicines Agency (EMA), the MAA process ensures a product’s quality, safety, and efficacy through a centralized procedure that leads to a single marketing authorization valid across all EU/EEA countries.
Click to read the full article.
In today’s global pharmaceutical landscape, companies increasingly aim for simultaneous or sequential marketing authorizations across multiple regions—such as the U.S., Europe, and Asia. However, regulatory agencies often require region-specific data to account for potential differences in drug response due to ethnic, environmental, or clinical practice factors. This is where bridging studies play a critical role.
Click to read the full article.
Module 1 of the electronic Common Technical Document (eCTD) may seem administrative, but it is critical to the success of any New Drug Application (NDA) submitted to the U.S. Food and Drug Administration (FDA). Unlike Modules 2–5, which follow ICH guidelines and are harmonized internationally, Module 1 is region-specific. For the FDA, Module 1 includes essential administrative, legal, and labeling information specific to U.S. regulatory requirements.
Click to read the full article.
Time is one of the most valuable resources in drug development. From submission to approval, regulatory review timelines significantly impact commercial launch strategies, market exclusivity, patient access, and global supply chain planning. However, these timelines vary considerably across regions, influenced by agency capacity, regulatory pathways, national guidelines, and priority programs.
Click to read the full article.
Labeling plays a critical role in the regulatory review of New Drug Applications (NDAs) and Biologics License Applications (BLAs). It defines how a product is prescribed, used, stored, and communicated to healthcare providers and patients. For regulators, especially the U.S. Food and Drug Administration (FDA), labeling ensures safety, efficacy, and informed decision-making.
Click to read the full article.
The U.S. Food and Drug Administration (FDA) has created multiple regulatory pathways to balance the need for rapid access to life-saving treatments with the requirement for robust evidence of safety and efficacy. Among these, the traditional approval pathway and the accelerated approval pathway are the most frequently discussed.
Click to read the full article.
In the regulatory review of New Drug Applications (NDAs) and Biologics License Applications (BLAs), advisory committees — commonly referred to as AdComms — play a vital role in providing independent scientific and clinical expertise. These external panels help the U.S. Food and Drug Administration (FDA) assess complex data, especially in cases involving novel therapies, high public health interest, or controversial benefit-risk profiles.
Click to read the full article.
